In recent years, Switzerland has consistently taken the path of liberalizing the use of cannabis for medical as well as non-medical purposes. This makes it easier for physicians to prescribe medicinal cannabis products. The pilot tests also include the possibility of consuming cannabis products containing THC for consumption purposes.
The consequence of this liberalization is a run by manufacturers of previously already legal cannabidiol (CBD) products onto the THC market. However, implementation in practice is often fraught with uncertainty - be it regulatory requirements or purely practical aspects.
The technical paper "Medical Cannabis and Pilot Trials in Switzerland" (German language) by Dr. Ralf Prescher, Senior Consultant gempex GmbH, addresses this situation.
The status quo is presented with a view to the regulatory requirements. Their impact on the market is examined in more detail and an outlook on possible developments is ventured.
Content cornerstones are:
- Legal framework for medical and non-medical use
- Pilot testing of cannabis for non-medical purposes
- GACP vs. GMP - what applies when and to what extent?
- Medical cannabis: the status quo
- Pilot testing: a difficult start
The German language article is available for download at GMP-Knowlege.
For questions on this topic, please contact Dr. Ralf Prescher via contact@gempex.com.
This might also interest you:
GMP for Cannabis - Growing and Production